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Abstract: Sildenaﬁ  l is a selective inhibitor of phosphodiesterase type 5 (PDE-5). Its chronic 
administration has been shown to improve exercise capacity, World Health Organization func-
tional class, and haemodynamics in patients with symptomatic pulmonary arterial hypertension 
(PAH). There is however, no data describing the clinical consequences of sudden cessation of 
sildenaﬁ  l treatment. In this series, 9 patients with NYHA Class II–IV PAH who were stable 
on 2 months of sildenaﬁ  l monotherapy, had their sildenaﬁ  l ceased to accommodate a 2-week 
washout period, required for enrollment in research involving an endothelin receptor antagonist. 
Six minute walk distance (SMWD) and clinical assessments were performed before cessation 
of sildenaﬁ  l, and again 2 weeks later. Over the course of this 2-week washout period, 6 of 
the 9 patients reported increased breathlessness and fatigue, 1 of these was hospitalized with 
worsening right heart failure. The SMWD fell in 6 patients, with falls of greater than 100 m 
recorded in 4 patients. This was accompanied by a worsening of NYHA Class from 2.5 ± 0.2 
to 3.1 ± 0.1 (mean ± SEM, p = 0.01). These data indicate that sudden cessation of sildenaﬁ  l 
monotherapy, in patients with PAH, carries with it a signiﬁ  cant and unpredictable risk of rapid 
clinical deterioration. We recommend that if sildenaﬁ  l needs to be ceased, it would be more 
prudent to consider concurrent vasodilator therapy before the gradual cessation of sildenaﬁ  l.
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Introduction
Sildenaﬁ  l is a selective inhibitor of phosphodiesterase type 5 (PDE-5). This is the 
predominant phosphodiesterase isoform in the lungs (Rabe et al 1994). Sildenaﬁ  l 
inhibits the breakdown of cGMP, and enhances the ability of endothelial nitric 
oxide to vasodilate the pulmonary arteries, reducing intravascular calcium, relaxing 
smooth muscle cells and reducing pulmonary vascular resistance (PVR) (Corbin 
et al 1999).
Acutely administered sildenaﬁ  l assists weaning from nitric oxide (Atz and Wessel 
1999), prolongs the effect of inhaled iloprost (Wilkens et al 2001; Ghofrani et al 
2002), reduces mean pulmonary artery pressure (MPAP) and PVR in the post heart 
transplant setting (Kulkarni et al 2004; Jabbour et al 2007), enhances the reduction in 
PVR when used concomitantly with iNO (Michelakis et al 2002; Lepore et al 2002) and 
modiﬁ  es pulmonary arterial hypertension (PAH) secondary to acute hypoxia in normal 
volunteers (Zhao et al 2001). Chronic administration of sildenaﬁ  l has been shown to 
improve exercise capacity, WHO functional class, and haemodynamics in patients with 
symptomatic PAH (Galie et al 2005). Similarly, hemodynamic and functional beneﬁ  t 
has been demonstrated in a small group of patients with PAH secondary to chronic 
thromboembolic disease (Sheth et al 2005). It is now established as a treatment for 
pulmonary hypertension in these patients. Though extensive data exist regarding the 
safety and efﬁ  cacy of sildenaﬁ  l therapy in PAH, there are no data describing the clinical 
consequences of sudden cessation of sildenaﬁ  l treatment.Vascular Health and Risk Management 2008:4(5) 1112
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Methods
In this series, 9 patients with NYHA Class II-IV PAH who 
were stable after 2 months of sildenaﬁ  l monotherapy 50mg, 
4 times daily were followed. This dose was chosen prior to 
the publication of research that demonstrated the efﬁ  cacy of 
sildenaﬁ  l 20 mg, 3 times daily in the treatment of PAH (Galie 
et al 2005). The average age of patients was 42 ± 13 years and 
the male to female ratio 5:4. Five patients were NYHA Class II, 
3 patients were NYHA Class III, and 1 patient was NYHA 
Class IV. Six patients had idiopathic PAH (iPAH) and 3 had 
chronic thromboembolic pulmonary hypertension (CTEPH).
Around this time a separate clinical trial of bosentan, an 
endothelin receptor antagonist was to commence. This trial 
required a 2-week washout period of previous PAH-speciﬁ  c 
therapy including sildenaﬁ  l. Nine patients wished to partici-
pate in the bosentan study and had their sildenaﬁ  l therapy 
ceased. In order to investigate the consequences of sildenaﬁ  l 
cessation, six minute walk distance (SMWD) and clinical 
assessments were performed before cessation of sildenaﬁ  l, 
and again 2 weeks after cessation, before commencing bosen-
tan. The study was approved by the St Vincent’s Hospital 
Human Research Ethics Committee and no external ﬁ  nancial 
support was received. Informed consent was given by all 
subjects. Importantly, there were no access arrangements 
for ongoing sildenaﬁ  l use for PAH, either as monotherapy or 
combination therapy in Australia at the time of study.
Results
Over the course of this 2-week washout period 6 of the 9 
patients reported increased breathlessness and fatigue, one 
was hospitalized with worsening right heart failure. The 
SMWD fell in 6 patients (3 with CTEPH and 3 with iPAH), 
with falls of greater than 100 m recorded in 4 patients 
(Figure 1). This was accompanied by a worsening of NYHA 
Class from 2.5 ± 0.2 to 3.1 ± 0.1 (mean ± SEM, p = 0.01). 
Deterioration was unrelated to the initial NYHA Class on 
sildenaﬁ  l. Fortunately, the condition of 4 of the 6 patients was 
stabilised with commencement of bosentan therapy. Two of 
the patients with CTEPH however, continued to deteriorate, 
one resumed sildenaﬁ  l and her condition restabilized, the 
other went on to have a successful pulmonary thromboen-
darterectomy (PTE) 2 months later. Three patients reported 
no change in their symptoms which correlated with stable 
SMWD.
Discussion
These data indicate that sudden cessation of sildenaﬁ  l mono-
therapy in patients with PAH carries with it a signiﬁ  cant and 
unpredictable risk of rapid clinical deterioration. “Rebound” 
pulmonary hypertension, which has been reported after 
withdrawal from calcium-antagonists (Rich and McLaughlin 
1999) and prostacyclin (Channick et al 2001) refers to a wors-
ening of PAH over and above what would be expected simply 
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Figure 1 Reduction in six minute walk distance after abrupt cessation of sildenaﬁ  l.Vascular Health and Risk Management 2008:4(5) 1113
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from the cessation of active treatment. To date, no such reports 
exist regarding sildenaﬁ  l. The theory that sildenaﬁ  l cessation 
may cause rebound PAH warrants further investigation with 
close hemodynamic monitoring, given the dramatic deteriora-
tion of the majority of patients in our series.
The ongoing deterioration of the 2 patients with 
CTEPH highlights another issue. Recent data presented 
at the European Society of Cardiology 2007 Congress by 
Lang and colleauges (BENEFiT Study subgroup analysis) 
demonstrated that bosentan improved hemodynamics but had 
no signiﬁ  cant effect on exercise capacity (6MWD) in patients 
with inoperable CTEPH and those with post-pulmonary 
endarterectomy PAH. Research into the effectiveness of 
bosentan in treating the broader group of patients with 
CTEPH is ongoing. In our series, the restabilization of the 
two patients with CTEPH, after PTE and sildenaﬁ  l therapy 
respectively, is consistent with current evidence-based 
management (Klepetko et al 2004; Sheth et al 2005). It is 
important to note that this series observed patients over a 
period of unavoidable cessation of sildenaﬁ  l monotherapy 
to gather valuable clinical information and was not designed 
to assess the effectiveness of bosentan therapy in rescuing 
patients off pulmonary vasodilator therapy.
In conclusion, we recommend that if sildenaﬁ  l needs to 
be ceased, that clinicians and patients should be aware of the 
potential risk of deterioration and patients should be closely 
monitored during this period. It may be more prudent to 
consider concurrent vasodilator therapy before the gradual 
cessation of sildenaﬁ  l.
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